SD Has No Potency Caps

SD Has No Statutory THC Potency Caps — 2026 Carley Bills Defeated 6–1 / 7–0

South Dakota does not impose statutory THC potency caps on flower or concentrates. In 2026, Sen. John Carley (R-Piedmont) introduced legislation that would have capped oils at 5% THC and liquid concentrates at 60% THC; the Senate Health and Human Services Committee rejected it 6–1. The same committee voted 7–0 against Carley’s separate bill (SB 181) that would have repealed the medical program 90 days after federal rescheduling.

Legal Disclaimer: This information reflects South Dakota cannabis law as of June 2026 and is for educational purposes only. It is not legal advice. Laws and regulations change — always verify current rules with the South Dakota Department of Health Medical Cannabis Program or a qualified attorney. Cannabis remains illegal under federal law.

Last verified: May 2026

What "No Potency Cap" Means

Unlike some state programs (Vermont caps THC content; some other states cap concentrate potency), SD has no statutory ceiling on the THC concentration of either flower or concentrate products. SD-licensed cultivators and manufacturers may produce products at the full natural and processed potency range:

Flower potency: typically 18–30% THC at SD dispensaries; some strains reach higher.
Live resin / sauce / sugar: typically 70–85% THC.
Distillate / wax / shatter: typically 75–95% THC.
Diamonds (THCa): 95–99% pre-decarbonation.
Vape cartridges: 70–90% THC.

Sen. Carley’s 2026 Potency-Cap Proposal

In 2026, Sen. John Carley (R-Piedmont) introduced legislation that would have:

Capped oils at 5% THC.
Capped liquid concentrates at 60% THC.

The Senate Health and Human Services Committee rejected the bill 6–1. The 5% oil cap would have effectively eliminated most tincture and vape-cart products from the SD market; the 60% concentrate cap would have eliminated most extract products (live resin, distillate, diamonds, etc.).

SB 181 — The Repeal-by-Trigger Bill

Sen. Carley separately introduced SB 181 in 2026 — a bill that would have repealed the SD medical-cannabis program 90 days after federal rescheduling. The bill was a procedural use of the federal-rescheduling event to dismantle the voter-approved IM 26 program.

The Senate Health and Human Services Committee rejected SB 181 7–0. Marijuana Policy Project commentary at the time: "Forty states have medical programs. None have repealed their state’s medical cannabis programs."

The 2025 Repeal Pattern

The 2026 votes followed a 2025 pattern in which Sen. Carley introduced similar repeal-and-restriction bills that the Senate likewise rejected. The pattern reflects:

Voter mandate constraint. IM 26 passed with 70% support — one of the strongest voter mandates of any state cannabis ballot measure. Legislators are reluctant to override that mandate.
Patient-population growth. By 2026, 18,759 SD residents held active medical-cannabis cards. Repealing the program would create a substantial rights-revocation issue.
Industry constituency. SD’s 70–81 licensed dispensaries, 24–35 cultivators, 17–19 manufacturers, and 2–6 testing labs constitute a meaningful economic constituency.
Tribal-program operations. The Flandreau Santee Sioux and Pine Ridge tribal cannabis programs operate independently of state law; state-program repeal would not eliminate tribal access.

The Travis Ismay Repeal Initiative (Stalled)

A separate medical-cannabis repeal initiative tied to activist Travis Ismay has circulated through the AG-statement and signature-gathering processes since 2023. As of May 2026, the initiative has not qualified for any ballot. The repeal initiative would impose direct-democracy reversal of IM 26 if it qualifies and passes.

The Constitutional Amendment L Backstop

The 2026 ballot includes Constitutional Amendment L, a legislatively referred amendment requiring future constitutional amendments to clear a 60% supermajority. If Amendment L passes, future cannabis constitutional amendments would face a substantially higher bar — making it more difficult to expand cannabis policy through ballot initiative. Amendment L does not directly affect IM 26 or the medical program (which are statutory, not constitutional), but it constrains future ballot-policy expansion.

Practical Implications

SD product slate is broad and high-potency. Patients have access to high-THC flower, concentrates, and vape products comparable to adult-use markets.
Repeal threats are real but unsuccessful. Sen. Carley’s 2025 + 2026 attempts have all failed in committee.
Federal rescheduling did not trigger state program changes. SB 181 was specifically designed to use rescheduling as the trigger; the bill failed.
The 2027 legislative session may see further repeal attempts. Sen. Carley remains in the Senate; the pattern is likely to recur.